Approval · Notice of Compliance 33034 · 2024
XULTOPHY: Notice of Compliance 33034
Issued April 9, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33034
- Date
- April 9, 2024
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XULTOPHY | Not yet assigned | — |
Medicinal ingredients
- LIRAGLUTIDE 3.6 MG per ML
- INSULIN DEGLUDEC 100 UNIT per ML